Immediate Ban of Benicar Demanded by Consumer Advocacy Group

Written By:
Jessie Paluch
Jessie Paluch

Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.

This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.

TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.

Immediate Ban of Benicar Demanded by Consumer Advocacy Group

On November 15th, 2017, Public Citizen, a consumer advocacy group with more than 400,000 members filed a Benicar ban petition demanding that the FDA remove popular high blood pressure drugs Azor, Benicar, Benicar HCT and Trebenzor from the market because of their association with a severe gastrointestinal injury, sprue-like enteropathy.   

Benicar, Azor, Benicar HCT and Tribenzor are widely prescribed angiotensin II receptor blocker (ARB) high blood pressure drugs containing olmesartan medoxomil.   

These four drugs have made Daiichi Sankyo, the manufacturer of all three just under $1 billion dollars annually for the past few years (2014 and 2015).  

Yet, the company has been aware of the link to this dangerous GI injury for years.

In the petition filed on November 15th, Public Citizen further noted that these olmesartan containing drugs manufactured by Daiichi Sankyo, Inc. offer no unique clinical benefits as compared to other ARBs so there should be no reason to remain on the market.

Sprue-like enteropathy causes serious morbidity.  

Individuals diagnosed with this disease experienced severe weight loss and malnutrition.  

Most required hospitalization, with some needing intensive care.  

Severe serum electrolyte abnormalities and acute kidney injury were among the complications of the enteropathy experienced by patients.   

Studies were able to pin-point the cause of the sprue-like enteropathy as coming from one of these drugs because the symptoms mostly disappeared after discontinuation of the medication and returned when patients started taking the medicine again.

Safety group petitions to Ban Benicar

The first olmesartan medoxomil drug was FDA approved in 2002 and within ten years, studies clearly pointed to a link between these drugs and sprue like enteropathy.  

Lawsuits filed on behalf of individuals suffering from sprue-like enteropathy allege that Daiichi Sankyo knew about this link and should have warned the public prior to 2012 when case reports were published in scientific medical journals.

The FDA warned of the link between Benicar and enteropathy in 2013 based on the review of 23 individuals reported to the FDA through the FAERS database.  

At that time, the FDA required that Daiichi Sankyo change their label to warn the public of the risk of sprue-like enteropathy.  

Public Citizen called this label change “weak” and “seriously deficient from a public health perspective.”

In August 2017, Daiiichi Sankyo agreed to pay up to $300 million in a Benicar lawsuit settlement intended compensate approximately 2,300 individuals who suffer from the life-altering disease sprue-like enteropathy.

The FDA will consider the petition and respond to Public Citizen.

Table of Contents
Written By:
Jessie Paluch
Jessie Paluch

Experienced Attorney & Legal SaaS CEO

With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three.  She spent the first decade of her career working as an international tax attorney at Deloitte.

In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.

In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!

Camp Lejeune Lawsuit

Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.

Tylenol Lawsuit

Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.

AFFF Lawsuit

Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.

Do You
Have A Case?

Here, at TruLaw, we’re committed to helping victims get the justice they deserve.

Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.

Would you like our help?

Helpful Sites & Resources